Given that BRAF mutations occur in more than 50% of melanoma cases, specific and potent BRAF inhibitors (BRAFis) like vemurafenib (VEM) evolved as targeted therapy for BRAFV600E mutant melanoma by curbing the mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) pathway. The gene discussed is WNK2; the disease is melanoma.